Quai MD Overview
Quai.MD is focused on helping healthcare systems improve patient care while also boosting revenue. The company’s AI-based clinical pathways platform provides a “clinical GPS” that enables physicians to navigate the care process safely and efficiently, resulting in increased hospital revenue. Quai mitigates care variability by standardizing physician’s decision making with an AI-based platform for personalized clinical pathways. Clinical pathways are decision trees, defined based on medical research, for patients with a certain condition. Quai captures these pathways, personalizes them using its proprietary AI-engine, and presents them to the physician at the point of care.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
BIRD Foundation approves $6.55 million for six new projects | CTech
The BIRD Foundation has approved $6.55 million in funding for six new projects between Israeli and American companies. The projects, which will also receive private-sector funding, will total $16 million in investment. The projects are in the fields of Environment, Electro-optics, Healthcare IT, and Quantum Computing. The companies involved include Amarel Embedded Solutions, Gleason Corporation, CyberRidge, Molex, Datos Health, Permanente Health Care Ventures, Groundwork BioAg, Indigo Agriculture Inc., Quai.MD, MUSC Health, Quantum Art, and BlueQubit Inc.
InvestmentPartners
growth-positive
AI Platform Helps Diagnose Chest Pain Swiftly And Accurately
Israeli startup Quai.MD has developed an AI-based platform to help doctors diagnose patients with chest issues in real time. The platform connects to a hospital’s Electronic Health Records (EHR) and uses this data, along with triage assessments and expert opinions drawn from medical research, to propose the most likely diagnosis and best courses of action. The company is currently focused on diagnosing the various causes of chest pain. The platform is expected to become operational in the emergency room at the Medical University of South Carolina at the start of 2024. The startup has raised around $2 million thus far and is now announcing a new $2.5 million financing round.
InvestmentPartners
growth-positive
Quai.MD and MUSC ink new deal to turn static clinical protocols into an AI-enhanced 'clinical GPS' for physicians
The Medical University of South Carolina health system (MUSC Health) and Quai.MD have entered into a strategic licensing agreement to advance their AI-based clinical pathways platform. This agreement will have a growth-positive impact on Quai.MD by improving physician productivity, patient outcomes, and hospital billing efficiency. Quai.MDs AI-engine tailors clinical pathways to each specific patient, reducing care variability. The implementation of the AI solution is set to begin in 2023.
Partners
growth-negative
ראיון עם שלומי עוזיאל, מנכ"ל Quai.MD כלכליסט
The CEO of SOS אקספרס is suspected of involvement in a massive invoice fraud. The article discusses the secrets behind the devaluation of אירודרום and the Smotrich method. It also mentions the crisis in the high-tech industry and the possibility of new restrictions on exporting AI chips to China. The impact on the company is growth-negative. The key theme of the article is the fraudulent activities and financial losses. The key issues discussed are related to customers. The article does not mention any specific customers, investors, acquisition or investment amounts, layoffs, or partners. The date of the event described in the article is not provided. Confidence level: 8.
Customers
